Document Detail


Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
MedLine Citation:
PMID:  23349006     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
This study evaluated whether the NCCSS truly improves the prognostic stratification of 630 consecutive de novo MDS patients and established which cytogenetic grouping [NCCSS or International Prognostic Scoring System (IPSS)], when combined with the WHO classification, best predicted the clinical outcome of myelodysplastic syndromes (MDS). The frequency of chromosomal defects was 53.8%. Clinical parameters, including number of cytopenias, WHO classification, IPSS cytogenetic categories and scores, NCCSS were all relevant for overall survival (OS) and leukemia-free survival (LFS) and were included in six distinct multivariate models compared by the Akaike Information Criterion (AIC). The most effective model to predict OS included the number of cytopenias, the WHO classification and the NCCSS, whereas the model including the number of cytopenias, blast cell percentage and the NCCSS and the model including the number of cytopenias the WHO classification and the NCCSS were almost equally effective to predict LFS. In conclusion, the NCCS (i) improves the prognostic stratification of the good and poor IPSS cytogenetic categories by introducing the very good and the very poor categories; (ii) is still incomplete in establishing the prognostic relevance of rare/double defects, (ii) applied to patients who receive supportive treatment only identifies five different prognostic subgroups, but applied to patients treated with specific therapies reveals only a trend toward a significantly different OS and LFS when patients of the poor and intermediate cytogenetic categories are compared, (iii) combined with the WHO classification is much more effective than the IPSS in predicting MDS clinical outcome. Am. J. Hematol. 88:120-129, 2013. © 2012 Wiley Periodicals, Inc.
Authors:
Paolo Bernasconi; Catherine Klersy; Marina Boni; Paola Maria Cavigliano; Irene Dambruoso; Rita Zappatore
Related Documents :
6590306 - Slight impairment of psychomotor skills in children after treatment of acute lymphoblas...
25030546 - 4-step 4-h carboplatin desensitization protocol for patients with gynecological maligna...
25032626 - 175 treatment outcomes and prognostic factors of pediatric glioblastoma multiforme.
23704196 - Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-cont...
21590116 - Quality of life in dukes' b and c colorectal carcinoma.
22632486 - Induction chemoradiation is not superior to induction chemotherapy alone in stage iiia ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of hematology     Volume:  88     ISSN:  1096-8652     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  120-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Affiliation:
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A high-confidence reference dataset of differentially expressed proteins in elongating cotton fiber ...
Next Document:  Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.